Related Experiment Video
Updated: Jul 18, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Impact of molecular profiling on clinical trial design for glioblastoma
Arnab Chakravarti1, Erin Tyndall, Kamalakannan Palanichamy
1Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, MA 02114, USA. achakravarti@partners.org
Abstract:
This review highlights the ways in which molecular and genetic profiling of malignant gliomas has led to intelligent clinical trial design. The review also highlights known resistance mechanisms to conventional therapies in malignant gliomas and potential strategies to overcome these mechanisms with the use of targeted therapy.
Insights
Molecular and genetic profiling of malignant gliomas informs clinical trial design. This review explores resistance mechanisms and targeted therapy strategies to overcome them in brain tumors.
Area of Science:
- Neuro-oncology
- Cancer Genomics
- Clinical Trial Design
Background:
- Malignant gliomas are aggressive brain tumors with poor prognoses.
- Conventional therapies often face significant challenges due to intrinsic or acquired resistance.
- Understanding the molecular landscape is crucial for therapeutic advancement.
Purpose of the Study:
- To review how molecular and genetic profiling guides intelligent clinical trial design for malignant gliomas.
- To highlight established resistance mechanisms to current treatments.
- To discuss potential targeted therapy strategies to overcome these resistance mechanisms.
Main Methods:
- Literature review of studies on molecular profiling in malignant gliomas.
- Analysis of resistance mechanisms in glioma treatment.
- Exploration of targeted therapy approaches.
Main Results:
- Molecular and genetic profiling have enabled more precise and effective clinical trial designs.
- Key resistance mechanisms to conventional therapies have been identified.
- Targeted therapies show promise in overcoming specific resistance pathways.
Conclusions:
- Personalized medicine approaches, driven by molecular insights, are transforming malignant glioma treatment.
- Targeted therapies represent a promising strategy to improve outcomes for patients with resistant gliomas.
- Continued research into glioma genomics and resistance is essential for developing novel therapeutic interventions.
